Melanoma Clinical Trials

About Melanoma trials

Melanoma trial design turns on histologic subtype (cutaneous, mucosal, acral, or uveal) and driver mutation status. BRAF mutations (V600E and V600K, present in roughly 50% of cutaneous melanoma) define eligibility for BRAF + MEK inhibitor trials and gate post-targeted-therapy trial design. NRAS mutations (about 20% of cutaneous) provide an alternative driver; trials for NRAS-mutant melanoma are an emerging space. KIT mutations are tested in mucosal and acral melanoma specifically, where they gate KIT inhibitor trials for the small but identifiable subgroup. NF1 loss occurs in roughly 14% of cutaneous melanoma and defines a "triple wildtype" subset (neither BRAF nor NRAS) with its own trial set. BAP1 is most relevant in uveal melanoma, where loss predicts metastatic risk and gates uveal-specific trials. PD-L1 (CD274) gates a subset of immunotherapy trials, though IO is now standard for melanoma regardless of PD-L1 expression in most settings.

Trial design in melanoma turns on histology and treatment context. Front-line metastatic cutaneous melanoma trials test new immunotherapy combinations (anti-PD1 + anti-CTLA4, anti-PD1 + anti-LAG3, novel checkpoint combinations) and new targeted-IO sequences for BRAF-mutant patients. Adjuvant trials enroll resected stage III or stage IV patients, testing IO monotherapy, IO combinations, and BRAF + MEK in BRAF-mutant patients. Neoadjuvant trials are an active area testing IO before surgery for resectable melanoma. Post-IO trials test TIL (tumor-infiltrating lymphocyte) therapy, IO rechallenge regimens, and novel mechanisms. Brain metastasis-active trials test combinations specifically designed to penetrate the CNS, often as separate cohorts within larger studies. Uveal melanoma trials are distinct, with HLA-A*02:01 testing required for some agents and a focus on liver-directed therapies for the predominant pattern of uveal metastasis. Mucosal and acral melanoma trials are smaller in number but distinct by biology and treatment response.

Melanoma trial eligibility centers on histology, BRAF status, and prior immunotherapy exposure. Histology subtype: cutaneous, mucosal, acral, and uveal melanoma trials are typically separated, with most metastatic trials targeting cutaneous specifically. BRAF V600E/V600K status determines eligibility for BRAF + MEK trials and influences sequencing in IO-targeted combinations. Prior immunotherapy exposure has become a foundational filter: most R/R trials specify whether patients are anti-PD1-naïve, anti-PD1-pretreated, or post-anti-PD1 progression specific, with similar distinctions for anti-CTLA4. Prior BRAF + MEK exposure for BRAF-mutant patients matters for trial line definition. Prior TIL therapy is becoming a relevant criterion as TIL enters earlier lines. Brain metastasis status with details on whether they're treated, stable, asymptomatic, or active. LDH is sometimes used as a stratification factor (high LDH carries worse prognosis). ECOG of 0 or 1 is standard. Autoimmune history may exclude patients from IO-heavy trials.

Biomarkers tested in Melanoma trials

These are the molecular markers most commonly required or evaluated in Melanoma eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.